A new class of drug to help protect the ears from infection by bacteria in the nasal cavity is making a comeback after being rejected in the early 2000s.
A new class is making its debut in a new spray, the epa-surgery drug scrubbing, disinfectant spray, and disinfectant that targets bacteria in nasal cavities, according to a statement released Wednesday by the Food and Drug Administration.
The drug was designed to be used in combination with a nasal decongestant, the FDA said.
The spray contains a disinfectant chemical that breaks down small bacteria, which then make it easier for the nasal decontamination process to begin.
This is the first time a drug like this has made it to market in a spray or a sprayable aerosol.
It’s the first drug in the series to be approved by the FDA and was approved for use by the National Institutes of Health in August.
The FDA said the drug is safe and effective for treating nasal infections caused by certain strains of bacteria, such as Pseudomonas aeruginosa.
The agency has not yet issued a full label or a recommended dose.
A second new spray was approved by regulators on Tuesday.
The new drug targets the same bacterial strain but has fewer ingredients and is designed to work with a larger number of bacteria in order to help treat more patients.
The new spray is available in two strengths, according the FDA.
One spray contains two doses of the spray that is formulated to be applied to the upper nasal region and the other spray has two doses that are formulated to work on the lower nasal region.
The FDA has not said when the spray will be available in a single dose.